NCT01955694 - Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2013

Primary Completion Date

January 23, 2015

Study Completion Date

February 20, 2015

Conditions

Heart Failure

Interventions

DRUG

BAY94-8862

2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets

DRUG

Eplerenone

INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets

DRUG

Placebo

matching placebo

Trial Locations (29)

489-8642

Seto

471-8513

Toyota

273-8588

Funabashi

296-8602

Kamogawa

790-0067

Matsuyama

818-8516

Chikushino-shi

660-8550

Amagasaki

650-0047

Kobe

654-0155

Kobe

311-3193

Higashiibaraki

254-8502

Hiratsuka

211-8533

Kawasaki

245-8575

Yokohama

611-0041

Uji

983-8520

Sendai

900-0005

Naha

902-8511

Naha

901-2132

Urasoe

350-1305

Sayama

525-8585

Kusatsu

162-8655

Shinjuku-ku

162-8666

Shinjuku-ku

400-8506

Kofu

810-0001

Fukuoka

892-0853

Kagoshima

607-8062

Kyoto

700-8607

Okayama

558-8558

Osaka

420-8630

Shizuoka